Uterine serous carcinoma (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Uterine serous carcinoma" in English language version.

refsWebsite
Global rank English rank
2nd place
2nd place
4th place
4th place
11th place
8th place

doi.org

  • Gründker C, Günthert AR, Emons G (2008). "Hormonal heterogeneity of endometrial cancer". Adv Exp Med Biol. Advances in Experimental Medicine and Biology. 630: 166–88. doi:10.1007/978-0-387-78818-0_11. ISBN 978-0-387-78817-3. PMID 18637491.
  • Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W (November 2014). "Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma". Int. J. Gynecol. Cancer. 24 (9 Suppl 3): S83–9. doi:10.1097/IGC.0000000000000264. PMID 25341586. S2CID 6505607.
  • Goldberg H, Miller RC, Abdah-Bortnyak R, Steiner M, Yildiz F, Meirovitz A, Villà S, Poortmans PM, Azria D, Zidan J, Ozsahin M, Abacioglu U, Gold DG, Amit A, Lavie O, Atahan IL, Kuten A (February 2008). "Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN)". Gynecol. Oncol. 108 (2): 298–305. doi:10.1016/j.ygyno.2007.10.037. PMID 18096209.
  • Sood BM, Jones J, Gupta S, Khabele D, Guha C, Runowicz C, Goldberg G, Fields A, Anderson P, Vikram B (September 2003). "Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma". Int J Radiat Oncol Biol Phys. 57 (1): 208–16. doi:10.1016/s0360-3016(03)00531-5. PMID 12909235.
  • Boruta DM, Gehrig PA, Fader AN, Olawaiye AB (October 2009). "Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review". Gynecol. Oncol. 115 (1): 142–53. doi:10.1016/j.ygyno.2009.06.011. PMID 19592079.
  • Huh WK, Powell M, Leath CA, Straughn JM, Cohn DE, Gold MA, Falkner CA, Carey DE, Herzog T, Fowler JM, Partridge EE, Kilgore LC, Alvarez RD (December 2003). "Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy". Gynecol. Oncol. 91 (3): 470–5. doi:10.1016/j.ygyno.2003.08.027. PMID 14675664.
  • Kelly MG, O'malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE (2005). "Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy". Gynecol Oncol. 98 (3): 353–9. doi:10.1016/j.ygyno.2005.06.012. PMID 16005947.
  • Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S (2008). "Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu". Int J Gynaecol Obstet. 102 (2): 128–31. doi:10.1016/j.ijgo.2008.04.008. PMID 18555254. S2CID 25674060.

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Gründker C, Günthert AR, Emons G (2008). "Hormonal heterogeneity of endometrial cancer". Adv Exp Med Biol. Advances in Experimental Medicine and Biology. 630: 166–88. doi:10.1007/978-0-387-78818-0_11. ISBN 978-0-387-78817-3. PMID 18637491.
  • Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W (November 2014). "Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma". Int. J. Gynecol. Cancer. 24 (9 Suppl 3): S83–9. doi:10.1097/IGC.0000000000000264. PMID 25341586. S2CID 6505607.
  • Goldberg H, Miller RC, Abdah-Bortnyak R, Steiner M, Yildiz F, Meirovitz A, Villà S, Poortmans PM, Azria D, Zidan J, Ozsahin M, Abacioglu U, Gold DG, Amit A, Lavie O, Atahan IL, Kuten A (February 2008). "Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN)". Gynecol. Oncol. 108 (2): 298–305. doi:10.1016/j.ygyno.2007.10.037. PMID 18096209.
  • Sood BM, Jones J, Gupta S, Khabele D, Guha C, Runowicz C, Goldberg G, Fields A, Anderson P, Vikram B (September 2003). "Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma". Int J Radiat Oncol Biol Phys. 57 (1): 208–16. doi:10.1016/s0360-3016(03)00531-5. PMID 12909235.
  • Boruta DM, Gehrig PA, Fader AN, Olawaiye AB (October 2009). "Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review". Gynecol. Oncol. 115 (1): 142–53. doi:10.1016/j.ygyno.2009.06.011. PMID 19592079.
  • Huh WK, Powell M, Leath CA, Straughn JM, Cohn DE, Gold MA, Falkner CA, Carey DE, Herzog T, Fowler JM, Partridge EE, Kilgore LC, Alvarez RD (December 2003). "Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy". Gynecol. Oncol. 91 (3): 470–5. doi:10.1016/j.ygyno.2003.08.027. PMID 14675664.
  • Kelly MG, O'malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE (2005). "Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy". Gynecol Oncol. 98 (3): 353–9. doi:10.1016/j.ygyno.2005.06.012. PMID 16005947.
  • Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S (2008). "Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu". Int J Gynaecol Obstet. 102 (2): 128–31. doi:10.1016/j.ijgo.2008.04.008. PMID 18555254. S2CID 25674060.

semanticscholar.org

api.semanticscholar.org